Prices are updated after-hours

Professional, Scientific, and Technical Services 3

Impel NeuroPharma Inc.

IMPL 4 | $0.2411 -77.19% 860K

(0.0% 1d) (0.0% 1m) (-76.5% 1y) (0.0% 2d) (10.1% 3d) (0.0% 7d) (-28.63% volume)
Earnings Calendar: 2024-03-22
Market Cap: $ 5,762,297
https://impelnp.com
Sec Filling | Patents | n/a employees

(US) Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.

parkinson treatment

add to watch list Paper trade email alert is off

Prometheus Biosciences Inc

RXDX | $199.92 0.02% 1.9M

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (3.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-47.11% volume)
Earnings Calendar: 2023-08-09
Market Cap: $ 9,558,822,541
https://www.prometheusbiosciences.com
Sec Filling | Patents | n/a employees

Prometheus Biosciences, Inc. is a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of IBD. The company's precision medicine platform, Prometheus360, combines proprietary bioinformatics discovery methods with one of the world's largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. Prometheus is headquartered in San Diego, CA.

diagnostics gastrointestinal treatment

add to watch list Paper trade email alert is off

Graphite Bio Inc

GRPH 4 | $3.27 1.84% 490K

Professional, Scientific, and T...

(0.0% 1d) (-2.8% 1m) (8.9% 1y) (0.0% 2d) (-2.8% 3d) (0.0% 7d) (-33.57% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 190,434,748
https://graphitebio.com
Sec Filling | Patents | 27 employees

Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications to transform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s platform allows it to precisely correct mutations, replace entire disease-causing genes with normal genes or insert new genes into predetermined, safe locations. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.

gene therapies

add to watch list Paper trade email alert is off

UpHealth Inc

UPH | $0.3 9.13% 0.0% 350K

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (-82.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (3.3% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 5,332,649
https://www.gigcapital2.com
Sec Filling | Patents | 2 employees

(United States) GigCapital Global is a Private-to-Public Equity investment group, sponsoring and operating Special Purpose Acquisition Companies ('SPAC', also known as Blank-Check companies). Founded in 2017 by Dr. Avi Katz, the GigCapital Group and its sponsored SPACs are led by an affiliated team of technology industry experts, deploying a unique Mentor-Investors™ methodology to partner with exceptional privately-held and U.S. and non-U.S. public technology companies led by dedicated, innovative entrepreneurs. The GigCapital Group companies offer financial, operational and executive mentoring to U.S. and global private, and non-U.S. public companies, in order to accelerate their path from inception and as a privately-held entity into the growth-stage as a publicly traded company in the U.S. The partnership of the GigCapital Group with these companies continues through an organic and roll-up strategy growth post the transition to a public company.

msa acquisitions spac blank check

add to watch list Paper trade email alert is off

NEXT-ChemX Corporation.

CHMX 4 | $4.5 0% 100

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (-57.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-27.54% volume)
Earnings Calendar:
Market Cap: $ 128,460,753

Sec Filling | Patents | n/a employees

(US)

add to watch list Paper trade email alert is off

Elvictor Group, Inc.

ELVG | $0.0125 225.6% 50K

Professional, Scientific, and T...

(0.0% 1d) (-0.8% 1m) (-68.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (0.0% volume)
Earnings Calendar:
Market Cap: $ 5,180,609

Sec Filling | Patents | n/a employees

add to watch list Paper trade email alert is off

Value Exchange International, Inc.

VEII 4 | $0.061 238.89% 23K

Professional, Scientific, and T...

(0.0% 1d) (34.4% 1m) (69.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (282.64% volume)
Earnings Calendar:
Market Cap: $ 2,653,546

Sec Filling | Patents | 300 employees

processing over us$ 20 billion worth in annual payment transactions at over 30,000 point of sale terminals for over 120 merchants, vei is recognized as the number #1 cloud based customer relationship management (crm) software service provider in the asia-pacific (apac) region. we’ve worked with retailers like a.s. watson group, 7-eleven, walmart, robinsons retail group; and with top technology partners like fujitsu, retalix, tencent, asiapay and more, to make your shopping experience even better. vei can help you drive new revenues and monetize your network in new and profitable ways. as the industry leader in innovative and collaborative technology solutions, vei can help you drive new revenues and monetize your network in new and profitable ways. vei’s solutions, platforms, and technologies provide a scalable, standards-based intelligent architecture that enables you to integrate subscriber knowledge with network and application intelligence in real-time to offer an expanding portfol

profitable spac

add to watch list Paper trade email alert is off

MDwerks, Inc.

MDWK | $0.21 -60.0% 2.5K

Professional, Scientific, and T...

(0.0% 1d) (-4.5% 1m) (600.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (150.0% volume)
Earnings Calendar:
Market Cap: $ 26,773,219

Sec Filling | Patents | 7 employees

learn about working at mdwerks. join linkedin today for free. see who you know at mdwerks, leverage your professional network, and get hired.

add to watch list Paper trade email alert is off

Organicell Regenerative Medicine, Inc.

OCEL | $2.75 -98.44% 3.4K

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (24674.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (6.51% volume)
Earnings Calendar:
Market Cap: $ 16,845,076

Sec Filling | Patents | 18 employees

organicell regenerative medicine, inc. processes, distributes, and supplies biologically processed cellular and tissue-based products in the united states. the company was formerly known as biotech products services and research, inc. and changed its name to organicell regenerative medicine, inc. in june 2018. organicell regenerative medicine, inc. has an agreement with regenerative care network to study potential therapeutic benefits of zofin for patients with heart failure. organicell regenerative medicine, inc. was founded in 2011 and is headquartered in miami, florida.

add to watch list Paper trade email alert is off

Ambrx Biopharma Inc - ADR

AMAM 4 | $28.0 0.0% 1.4M

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (139.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (117.58% volume)
Earnings Calendar:
Market Cap: $ 1,768,206,832
https://ambrx.com
Sec Filling | Patents | n/a employees

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, the company has clinical collaborations with Bristol Myers Squibb, Astellas, BeiGene, Sino Biopharma, Elanco and NovoCodex, for drug candidates generated using Ambrx technology.

urea antibody genetic cardiovascular optical metabolic

add to watch list Paper trade email alert is off

Beauty Health Company (The) - Class A

SKIN | $3.25 -5.25% -5.54% 1.2M

Professional, Scientific, and T...

(0.0% 1d) (-24.1% 1m) (-75.1% 1y) (0.0% 2d) (0.0% 3d) (-7.0% 7d) (8.5% volume)
Earnings Calendar: 2024-03-12
Market Cap: $ 401,242,800
https://www.beautyhealth.com/
Sec Filling | Patents | n/a employees

BeautyHealth is a category-creating beauty health company focused on bringing innovative products to market. Its flagship brand, HydraFacial, is a non-invasive and approachable beauty health platform and ecosystem with a powerful community of estheticians, consumers and partners, bridging medical and consumer retail to democratize and personalize skin care solutions for the masses. Leading the charge in beauty health as a category-creator, HydraFacial uses a unique delivery system to cleanse, extract, and hydrate with their patented hydradermabrasion technology and super serums that are made with nourishing ingredients, providing an immediate outcome and creating an instantly gratifying glow in just three steps and 30 minutes. HydraFacial® and Perk™ products are available in over 87 countries with over 16,000 delivery systems globally and millions of treatments performed each year.

brands msa skin treatment 3d

add to watch list Paper trade email alert is off

Synaptogenix Inc

SNPX | $4.33 -7.08% -7.62% 30K

Professional, Scientific, and T...

(0.0% 1d) (2341.5% 1m) (380.0% 1y) (0.0% 2d) (0.0% 3d) (8.6% 7d) (30.76% volume)
Earnings Calendar:
Market Cap: $ 117,487,401

Sec Filling | Patents | 5 employees

synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases.

add to watch list Paper trade email alert is off

Vivakor, Inc.

VIVK | $1.1 12.25% 10.91% 350K

Professional, Scientific, and T...

(0.0% 1d) (1.4% 1m) (-17.9% 1y) (0.0% 2d) (0.0% 3d) (-3.3% 7d) (-17.23% volume)
Earnings Calendar:
Market Cap: $ 30,481,278

Sec Filling | Patents | 25 employees

vivakor inc is a company based out of 2590 holiday rd ste 100, coralville, iowa, united states.

add to watch list Paper trade email alert is off

Day One Biopharmaceuticals Inc

DAWN 4 | $14.98 -4.89% -5.14% 1.4M

Professional, Scientific, and T...

(0.0% 1d) (-0.4% 1m) (12.4% 1y) (0.0% 2d) (0.0% 3d) (5.5% 7d) (22.59% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 1,308,909,902
https://dayonebio.com
Sec Filling | Patents | 20 employees

(US) Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers. Day One was founded to address a critical unmet need: children with cancer are being left behind in a cancer drug development revolution. Its name was inspired by the “The Day One Talk”1 that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. The company aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One. Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, DAY101, is an oral, highly-selective type II pan-RAF kinase inhibitor, and is being evaluated in a pivotal Phase 2 clinical trial (FIREFLY-1) in pediatric, adolescent and young adult patients with recurrent or progressive low-grade glioma (pLGG). The Company’s pipeline also includes the investigational agent pimasertib, a clinical-stage, oral, small molecule found to selectively inhibit mitogen-activated protein kinase kinases 1 and 2 (MEK). Through Day One and its collaborators, cancer drug development comes of age. Day One is based in South San Francisco.

treatment diagnostics cancer

add to watch list Paper trade email alert is off

Xilio Therapeutics Inc

XLO | $1.16 -9.38% -10.34% 340K

Professional, Scientific, and T...

(0.0% 1d) (85.2% 1m) (-56.6% 1y) (0.0% 2d) (4.1% 3d) (1.6% 7d) (120.11% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 39,989,244
https://xiliotx.com
Sec Filling | Patents | 2021 employees

Xilio Therapeutics is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The company is using its proprietary geographically precise solutions (GPS) platform to rapidly engineer novel molecules, including cytokines and other biologics, that are designed to optimize their therapeutic index. These molecules are designed to localize activity within the tumor microenvironment without systemic effect, resulting in the potential to achieve enhanced anti-tumor activity. Xilio is building a pipeline of wholly-owned, tumor-selective, GPS-enabled cytokine and checkpoint inhibitor product candidates, including XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody; XTX202, a tumor-selective IL-2; XTX301, a tumor-selective IL-12; and XTX401, a tumor-selective IL-15.

cancer optical

add to watch list Paper trade email alert is off

Werewolf Therapeutics Inc

HOWL | $5.91 0.68% 0.68% 120K

Professional, Scientific, and T...

(0.0% 1d) (-3.9% 1m) (142.6% 1y) (0.0% 2d) (0.5% 3d) (6.9% 7d) (-70.97% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 256,182,915
https://werewolftx.com
Sec Filling | Patents | n/a employees

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is leveraging its proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors.The company is continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

cancer immunotherapy msa treatment

add to watch list Paper trade email alert is off

Finch Therapeutics Group Inc

FNCH | $2.205 -6.57% -7.03% 30K

Professional, Scientific, and T...

(0.0% 1d) (-8.0% 1m) (-79.0% 1y) (0.0% 2d) (0.0% 3d) (12.2% 7d) (-81.77% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 3,540,707
https://finchtherapeutics.com
Sec Filling | Patents | n/a employees

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for the treatment of ulcerative colitis and Crohn’s disease, respectively.

hepatitis gastrointestinal treatment injection

add to watch list Paper trade email alert is off

Compass Therapeutics Inc

CMPX | $1.48 -0.67% -0.68% 230K

Professional, Scientific, and T...

(0.0% 1d) (-25.9% 1m) (-43.5% 1y) (0.0% 2d) (0.0% 3d) (2.3% 7d) (Infinity% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 203,631,973

Sec Filling | Patents | 26 employees

compass therapeutics is an antibody discovery and development company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. compass is industrializing antibody discovery and decentralizing biologic validation through a partnership-first mentality that leverages best-in-class technologies and top-tier academic laboratories around the world. novel scientific insights are validated and explored deeply inside our labs before compass pursues the best proprietary combinations of therapeutics into human clinical trials. in 2015, compass quietly closed a $120mm series a financing to fund our ambitious plan to build a fully-integrated biopharmaceutical company from the ground up. our investors are among the most sophisticated venture capitalists in the industry who exemplify our philosophy of building long term economic value only by delivering therapeutics with meaningful efficacy beyond

add to watch list Paper trade email alert is off

Vera Therapeutics Inc - Class A

VERA | $37.96 -3.85% -4.0% 1.4M

Professional, Scientific, and T...

(0.0% 1d) (-11.7% 1m) (539.1% 1y) (0.0% 2d) (0.0% 3d) (-14.0% 7d) (-18.68% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 2,066,999,021

Sec Filling | Patents | 46 employees

trucode gene repair is advancing its novel triplex gene editing platform to potentially cure devastating genetic diseases, with initial focus on sickle cell disease and cystic fibrosis. the elegance of triplex gene editing lies in its ability to harness natural, high-fidelity dna repair mechanisms, and its independence from the requirement for exogenous nucleases and viral vectors.

t-cell

add to watch list Paper trade email alert is off

1847 Holdings LLC

EFSH 4 | $2.1 21.39% 2.86% 250K

Professional, Scientific, and T...

(0.0% 1d) (39.5% 1m) (-95.5% 1y) (0.0% 2d) (0.0% 3d) (-1.7% 7d) (14.97% volume)
Earnings Calendar:
Market Cap: $ 1,922,720

Sec Filling | Patents | 26 employees

1847 holdings llc, through its subsidiaries, provides a range of products and services for agriculture, construction, lawn, and garden industries in north america. it operates through two segments, land management services, and retail and appliances. the land management services segment provides waste disposal and various agricultural services, such as manure spreading, land rolling, bin whipping, cleaning of bulk storage bins and silos, equipment rental, trucking, vacuuming, building erection, various shop, and other services to local agricultural and farming communities; and wholesales agricultural equipment and parts. the retail and appliances segment provides a range of appliance services, including sales, delivery/installation, in-home service and repair, extended warranties, and financing to homeowners, builders, and designers. the company also designs, builds, and installs custom cabinetry primarily for custom and semi-custom builders. 1847 partners llc serves as the manager of

add to watch list Paper trade email alert is off